(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.03%.
Celcuity's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast CELC's revenue for 2026 to be $1,848,207,097, with the lowest CELC revenue forecast at $479,532,698, and the highest CELC revenue forecast at $2,974,081,368. On average, 12 Wall Street analysts forecast CELC's revenue for 2027 to be $19,664,265,868, with the lowest CELC revenue forecast at $9,883,266,778, and the highest CELC revenue forecast at $30,537,914,464.
In 2028, CELC is forecast to generate $39,314,341,483 in revenue, with the lowest revenue forecast at $20,859,672,380 and the highest revenue forecast at $67,428,169,224.